banner

Posts tagged as: regenerative medicine news back to homepage

EC Approval of Glybera A Significant Industry Milestone in Gene Therapy EC Approval of Glybera A Significant Industry Milestone in Gene Therapy(0)

Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies.  The EC approval marks Glybera as the first gene therapy to be approved in the Western world. Read More

OTCBB News

Electronic Control Security Lands Prime Government Contract Electronic Control Security Lands Prime Government Contract(0)
Balqon Lithium Battery System Installed in Hybrid Yacht Balqon Lithium Battery System Installed in Hybrid Yacht(0)
Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)
ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)
Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)
Drinks Americas Signs Sales Agreement for Marigold Craft Beer Drinks Americas Signs Sales Agreement for Marigold Craft Beer(0)
read more


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Gateways

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories
Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.